Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dror Michaelson

Showing results (41-50 of 121) with videos related to

Pageof 13
Sort By:
Cancer|June 20, 2007
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisoneJonathan E Rosenberg, Vivian K Weinberg, W Kevin Kelly, et al.
Journal of Oncology Practice|September 22, 2010
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfaDavid Cella, Joseph C Cappelleri, Andrew Bushmakin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancerM Dror Michaelson, Donald S Kaufman, Hang Lee, et al.
Cancer|August 23, 2008
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Ronald M Bukowski, Robert A Figlin, et al.
Journal of Oncology Practice|January 9, 2014
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancerAyal A Aizer, Jonathan J Paly, M Dror Michaelson, et al.
Clinical Genitourinary Cancer|July 17, 2017
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical TrialsNizar M Tannir, Robert A Figlin, Martin E Gore, et al.
American Journal of Physiology. Renal Physiology|December 2, 2004
Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopyRachel Katz-Brull, Neil M Rofsky, Martina M Morrin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Phase II study of sunitinib in men with advanced prostate cancerM Dror Michaelson, M M Regan, W K Oh, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 18, 2024
Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate CancerTimothy W Churchill, Matthew R Smith, M Dror Michaelson, et al.
Cancer|June 11, 2015
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinomaM Dror Michaelson, Rana R McKay, Lillian Werner, et al.
Pageof 13

Showing results (41-50 of 121) with videos related to

Sort By:
Pageof 13
Cancer|June 20, 2007
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisoneJonathan E Rosenberg, Vivian K Weinberg, W Kevin Kelly, et al.
Journal of Oncology Practice|September 22, 2010
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfaDavid Cella, Joseph C Cappelleri, Andrew Bushmakin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2007
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancerM Dror Michaelson, Donald S Kaufman, Hang Lee, et al.
Cancer|August 23, 2008
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Ronald M Bukowski, Robert A Figlin, et al.
Journal of Oncology Practice|January 9, 2014
Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancerAyal A Aizer, Jonathan J Paly, M Dror Michaelson, et al.
Clinical Genitourinary Cancer|July 17, 2017
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical TrialsNizar M Tannir, Robert A Figlin, Martin E Gore, et al.
American Journal of Physiology. Renal Physiology|December 2, 2004
Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopyRachel Katz-Brull, Neil M Rofsky, Martina M Morrin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2009
Phase II study of sunitinib in men with advanced prostate cancerM Dror Michaelson, M M Regan, W K Oh, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|March 18, 2024
Cardiac Structural Changes and Declining Cardiorespiratory Fitness During Androgen Deprivation Therapy for Prostate CancerTimothy W Churchill, Matthew R Smith, M Dror Michaelson, et al.
Cancer|June 11, 2015
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinomaM Dror Michaelson, Rana R McKay, Lillian Werner, et al.
Pageof 13